WAT Medical has secured a MOHAP manufacturing site certificate. The paid press release, issued from Vancouver, BC on 17 June 2026 via PR Newswire, states that the UAE Ministry of Health & Prevention granted a Manufacturing Site Registration Certificate, confirming that its facilities meet local medical‑device production standards. The approval adds to the firm’s existing clearances from the U.S. Food and Drug Administration, Health Canada and Australia’s TGA, as well as its MDSAP and ISO 13485 certifications, all of which are recognised benchmarks for quality and safety.
Regulatory Milestone Strengthens Global Footprint
The new certificate underscores WAT Medical’s commitment to meeting rigorous international standards. With more than 10 years of industry experience, the company has completed over 10 core clinical studies that demonstrate the safety and effectiveness of its wearable neuromodulation technologies. These studies support the company’s portfolio of non‑invasive devices, which target chronic conditions such as nausea, motion sickness and migraine. By holding MDSAP and ISO 13485 recognitions, WAT Medical signals to regulators worldwide that its production processes adhere to the highest quality management criteria. By aligning its manufacturing processes with UAE regulations, WAT Medical reinforces a global regulatory network that already spans North America and Australia.
The combination of FDA, Health Canada and TGA approvals, together with MDSAP and ISO 13485 recognitions, positions the firm to accelerate product launches in new markets while maintaining compliance across jurisdictions. This alignment also simplifies the pathway for future submissions in regions that reference UAE standards as a reference point.
Strategic Expansion into the Middle East
Following the registration, WAT Medical will work with its officially appointed authorized representative in the UAE to advance product registration for its neuromodulation devices HeadaTerm and EmeTerm. Once cleared, the company intends to roll out distribution across the UAE and then broaden its reach into other Middle Eastern markets, leveraging the region’s growing demand for non‑pharmacological treatment options. The firm also plans to showcase its products during Amazon Prime Day 2026, marking its tenth participation in the global shopping event. The Middle East’s healthcare sector is rapidly expanding, and the UAE’s well‑established regulatory framework and strategic geographic location make it an ideal entry point for regional growth.
As part of its expansion plan, WAT Medical aims to forge new research collaborations with local institutions, building on existing partnerships with Ohio State University and Concordia University in the United States and Canada. These collaborations are intended to deepen scientific insight into neuromodulation therapies and support the company’s broader innovation agenda.
Frequently asked questions
What is a MOHAP manufacturing site certificate and why is it important for medical device companies in the UAE?A MOHAP manufacturing site certificate is issued by the UAE Ministry of Health & Prevention to confirm that a company's facilities meet local medical‑device production standards, allowing the firm to manufacture and distribute devices within the UAE market.
Which regulatory approvals does WAT Medical hold besides the UAE MOHAP certificate?WAT Medical already has clearances from the U.S. FDA, Health Canada, Australia’s TGA, as well as MDSAP and ISO 13485 certifications, all recognised benchmarks for quality and safety.
How will the MOHAP registration help WAT Medical launch its neuromodulation devices in the Middle East?The registration enables WAT Medical to work with its authorised UAE representative to pursue product registration for its HeadaTerm and EmeTerm devices, paving the way for distribution across the UAE and later expansion into other Gulf markets.
When did WAT Medical announce its MOHAP manufacturing site certification?The press release announcing the MOHAP manufacturing site certificate was issued on 17 June 2026 from Vancouver, BC via PR Newswire.
